Colgate-Palmolive Company
CL
$93.15
-0.13%
Colgate-Palmolive Company is a global leader in consumer products, manufacturing oral care, personal care, home care, and pet nutrition products sold in over 200 countries. Its oral care line accounts for over 40% of total sales, and its Hill's Pet Nutrition segment contributes nearly a quarter, with a strong presence in emerging markets. The company is recognized as a defensive, stable compounder in the Household & Personal Products industry, with a brand portfolio that commands strong shelf presence and pricing power. Currently, investor attention is focused on its ability to sustain organic growth amid input cost inflation, its premium valuation relative to peers, and the recent rotation into defensive value stocks, which has supported its share price despite mixed quarterly results.…
CL
Colgate-Palmolive Company
$93.15
Investment Opinion: Should I buy CL Today?
Based on the analysis, CL is rated a Hold. The consensus analyst rating is 'Buy' with an average target of $98.95, implying 6.4% upside, but the premium valuation and high debt limit the risk-reward. The thesis is that CL is a high-quality defensive compounder, but current pricing already reflects much of its growth potential. Supporting evidence includes: trailing PE of 29.9x vs. forward PE of 22.7x, indicating expected earnings growth of 32%; revenue growth of 8.4% YoY in Q1 2026; gross margin of 60.6%; and TTM free cash flow of $3.77B. However, the negative PEG ratio and high payout ratio suggest limited margin of safety. The biggest risks are valuation compression if growth decelerates, and debt servicing costs if rates stay high. This Hold would upgrade to Buy if the stock pulls back to below $85 (forward PE <20x) or if revenue growth sustains above 10%, and downgrade to Sell if revenue growth falls below 5% or margins deteriorate. Overall, CL is fairly valued relative to its history and peers, with a slight premium that is justified by its defensive quality.
Sign up to view all
CL 12-Month Price Forecast
The AI assessment is neutral with medium confidence. CL's fundamentals are solid, but the valuation is full, and the market's growth expectations may be optimistic given the negative PEG ratio. The stock's defensive characteristics make it a stable holding, but upside is limited unless growth accelerates further. Key factors to watch include margin trends and revenue growth sustainability. If revenue growth exceeds 10% and margins expand, the stance would upgrade to bullish; if growth decelerates below 5%, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.95 and implied upside of +6.2% versus the current price.
Average Target
$98.95
0 analysts
Implied Upside
+6.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
The target price range spans from $87.00 (low) to $110.00 (high), a spread of $23.00, reflecting moderate uncertainty. The low target implies a downside of -6.5% from current levels, while the high target suggests an upside of 18.3%. The high target likely assumes continued margin expansion and successful premiumization, while the low target may factor in input cost pressures or a consumer slowdown. Recent ratings actions have been predominantly positive, with Citigroup, UBS, RBC Capital, and JP Morgan reaffirming Buy/Overweight ratings in May and July 2026, and Rothschild upgrading from Neutral to Buy in April 2026. This pattern suggests analysts are becoming more confident in the company's growth prospects, though the wide target range indicates that the market is not fully aligned on the pace of recovery.
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a classic defensive growth profile with accelerating revenue, strong margins, and robust cash flow, but its premium valuation and high debt temper the bullish case. The bull case is supported by solid fundamentals and analyst optimism, while the bear case hinges on valuation risk and potential earnings volatility. Currently, the evidence slightly favors the bulls due to improving growth and defensive appeal, but the key tension is whether the market's growth expectations (forward PE 22.7x) are justified by the company's ability to sustain margin expansion and revenue acceleration. If growth disappoints, the stock could de-rate significantly.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 8.41% YoY to $5.324B, accelerating from 5.9% in the prior quarter, driven by price increases and volume recovery. This marks the strongest growth in recent quarters, indicating successful pricing power and resilient consumer demand.
- High Gross Margin Expansion: Gross margin improved to 60.59% in Q1 2026, up from 60.82% a year ago, reflecting effective cost management and premiumization. Operating margin also expanded to 21.71%, supporting earnings growth.
- Strong Analyst Support: With 20 analysts, the consensus rating is 'Buy' (mean 2.05), and the average target price of $98.95 implies 6.4% upside. Recent upgrades from Rothschild and reaffirmations from Citigroup, UBS, RBC, and JP Morgan signal growing confidence.
- Defensive Characteristics: Beta of 0.327 indicates low market correlation, making CL a defensive anchor in portfolios. The stock has outperformed the S&P 500 YTD (+19.7% vs +12.7%), benefiting from rotation into defensive value.
Bearish
- Elevated Valuation: Trailing PE of 29.93x and forward PE of 22.68x are at a premium to historical averages and peers. The PEG ratio is negative (-1.19) due to near-term earnings decline, suggesting the market may be overpaying for growth.
- Negative EPS Growth in Q4 2025: Q4 2025 reported a net loss of -$37M and EPS of -$0.046, driven by a $970M other expense. This volatility in earnings raises concerns about the stability of profitability.
- High Debt Levels: Debt-to-equity ratio of 147.9% indicates significant leverage, which could strain cash flows if interest rates remain high. Interest expense of $62M in Q1 2026 is a notable burden.
- Underperformance vs. Market: Over the past year, CL gained 9.92% vs. S&P 500's 21.46%, underperforming by 11.5%. Relative strength is negative across 1M, 6M, and 1Y periods, indicating lack of momentum.
CL Technical Analysis
Colgate-Palmolive's stock is in a clear uptrend over the past year, with a 1-year price change of +9.92%, though it has underperformed the S&P 500's +21.46% gain. The current price of $93.00 sits at approximately 83% of its 52-week range (low $74.55, high $99.33), indicating the stock is closer to its highs than its lows, reflecting a defensive bid but not an overextended momentum move. This positioning suggests investors are treating CL as a safe haven, but the relative underperformance versus the broader market highlights a lack of aggressive buying interest.
Beta
0.33
0.33x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+10.0%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +1.0% | +2.4% |
| 3m | +6.5% | +4.7% |
| 6m | -2.3% | +11.7% |
| 1y | +10.0% | +21.3% |
| ytd | +19.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth has been steady but modest, with the most recent quarter (Q1 2026) showing revenue of $5.324 billion, up 8.41% year-over-year, accelerating from the prior quarter's 5.9% growth. The company's revenue trajectory has been consistently positive, with quarterly revenues rising from $4.911 billion in Q1 2025 to $5.324 billion in Q1 2026, a 8.4% increase. Growth is driven by both segments, with Oral, Personal and Home Care contributing $4.034 billion and Pet Nutrition $1.196 billion in the latest quarter, though the pet segment is growing faster. This acceleration suggests the company is successfully passing through price increases and benefiting from volume recovery, supporting the investment case for a defensive grower.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given that Colgate-Palmolive is profitable, the PE ratio is the primary valuation metric. The trailing PE is 29.93x, while the forward PE is 22.68x, indicating the market expects earnings growth of about 32% (from trailing EPS of $3.11 to forward EPS of $4.10). This gap implies the market is pricing in a significant acceleration in earnings, likely driven by margin expansion and continued revenue growth. The PEG ratio is negative (-1.19) due to negative earnings growth expectations in the near term, which is unusual and warrants caution.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 147.9%, which amplifies interest expense and reduces financial flexibility. The payout ratio of 85.5% leaves minimal cushion for dividend sustainability, and the negative EPS in Q4 2025 highlights earnings volatility. Additionally, the company's reliance on continued revenue growth to justify its forward PE of 22.7x means any slowdown could trigger multiple compression. Market risks include valuation compression risk given the premium to peers; the stock's beta of 0.327 offers low correlation but also limits upside in strong markets. Competitive pressures in oral care and pet nutrition, along with regulatory scrutiny on product claims, could erode market share. Macro risks include sensitivity to input cost inflation and currency fluctuations, as 70% of sales are international. In a worst-case scenario, a combination of rising input costs, consumer downtrading, and a broader market sell-off could drive the stock down to its 52-week low of $74.55, representing a -19.8% downside from the current price of $93.00. This would be exacerbated by the high debt load and potential dividend cut, leading to a loss of investor confidence.
FAQ
The key risks are: 1) Valuation risk - the stock trades at a premium (forward PE 22.7x), and any growth disappointment could lead to multiple compression. 2) Financial risk - high debt-to-equity of 147.9% and a payout ratio of 85.5% leave little room for error. 3) Competitive risk - private label brands and new entrants could erode market share. 4) Macro risk - input cost inflation and currency fluctuations, especially with 70% international sales. The most severe risk is a combination of these factors leading to a -19.8% decline to the 52-week low.
The 12-month forecast is moderately bullish. The bull case (25% probability) targets $100-$110, driven by sustained growth and margin expansion. The base case (50% probability) targets $93-$99, in line with the analyst average of $98.95. The bear case (25% probability) targets $80-$87, if growth slows or costs rise. The most likely scenario is the base case, assuming revenue growth of ~7% and stable margins. Investors should monitor quarterly earnings for signs of acceleration or deceleration.
CL is currently fairly valued to slightly overvalued. The trailing PE of 29.93x is above the 5-year average of ~25x, and the forward PE of 22.68x is also at a premium to peers like P&G (forward PE ~20x). The PEG ratio is negative (-1.19) due to expected near-term earnings decline, which is a red flag. The market is pricing in significant earnings growth (32% from trailing to forward), which may be optimistic. Relative to its own history, the stock is trading near the higher end of its valuation range, suggesting limited upside unless growth accelerates.
CL is a good buy for investors seeking a defensive, income-generating stock with moderate growth. The analyst consensus is 'Buy' with an average target of $98.95, implying 6.4% upside. However, the stock trades at a premium valuation (forward PE 22.7x), so the risk-reward is balanced. The biggest downside risk is a -19.8% drop to the 52-week low of $74.55 if growth disappoints. For long-term investors with a horizon of 3+ years, CL can be a solid addition, but for short-term traders, the upside may be limited.
CL is best suited for long-term investment. With a beta of 0.327, it is a low-volatility stock that provides stability and income, making it ideal for buy-and-hold investors. The company's consistent cash flow and dividend yield of 2.85% support a long-term horizon of 5+ years. Short-term trading is possible but less attractive due to limited upside and high valuation. The stock's defensive nature means it may underperform in strong bull markets, but it offers downside protection. A minimum holding period of 3 years is recommended to ride out valuation fluctuations.